Literature DB >> 29739049

Expression Patterns of CXCL12 and its Receptor in Colorectal Carcinoma.

Ashraf Mousavi, Shahryar Hashemzadeh, Tayyeb Bahrami, Mehrdad Asghari Estiar, Mohammad A H Feizi, Nasser Pouladi, Leila Rostamizadeh, Ebrahim Sakhinia.   

Abstract

BACKGROUND: Stromal cell-derived factor-1 (also called CXCL12) and its receptor, CXCR4, have a key role in the pathogenesis and tumorigenesis of various cancers. The aims of the current study were to quantitatively examine the expression of CXCR4 and CXCL12 genes in colorectal cancer and to correlate their expression degree with clinicopathological features.
METHODS: Tumor tissue samples were collected from 47 patients with CRC. Total RNA was isolated from resection tissues and real-time PCR analysis was performed to examine mRNA levels of CXCL12 and CXCR4 genes.
RESULTS: No significant differences were observed for both CXCL12 and CXCR4 between tumor tissues and the adjacent non-affected tissues, although a borderline significant correlation (p = 0.052) were detected between gene expression of CXCL12 and CXCR4 in tumor tissues. Our results also indicated that there was no significant correlation between expression pattern of CXCL12/CXCR4 and clinicopathological variables.
CONCLUSIONS: Our data showed that CXCL12 and CXCR4 are expressed simultaneously in colorectal carcinoma tissues, suggesting that expression of these chemokines and corresponding receptors may play a pivotal role in colorectal tumorigenesis, although it cannot be as a predictive factor for disease progression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29739049     DOI: 10.7754/Clin.Lab.2017.170913

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  1 in total

Review 1.  Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.

Authors:  Aïssata Aimée Goïta; Dominique Guenot
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.